NeoGenomics, Inc. (OQ:NEO)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
 
See Regulatory Filings on SEC
Company Contact
Address: 12701 Commonwealth Dr Ste 9
FORT MYERS FL 33913-8626
Tel: 1-239-6904239
Website: https://neogenomics.com
IR: See website
<
Key People
Douglas M. VanOort
Chairman of the Board, Chief Executive Officer
William B. Bonello
President, Informatics and Director of Investor Relations
George A. Cardoza
President - Pharma Services Division
Kathryn B. McKenzie
Chief Financial Officer
Robert J. Shovlin
President - Clinical Services Division
Cynthia Dieter
Chief Accounting Officer, Controller
Steven A. Ross
Chief Information Officer
Stephanie K. Bywater
Chief Compliance Officer
Jennifer M. Balliet
Vice President, Chief Culture Officer
Denise E. Pedulla
General Counsel, Corporate Secretary
   
Business Overview
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.
Financial Overview
For the six months ended 30 June 2020, NeoGenomics, Inc. revenues decreased 2% to $193M. Net loss increased from $433K to $13.8M. Revenues reflect Clinical testing segment decrease of 5% to $166.9M. Higher net loss reflects General and administrative increase of 14% to $64.6M (expense), Loss on extinguishment of debt increase of 38% to $1.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.01 to -$0.13.
Employees: 1,700 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $3,746M as of Jun 30, 2020
Annual revenue (TTM): $404.55M as of Jun 30, 2020
EBITDA (TTM): $18.79M as of Jun 30, 2020
Net annual income (TTM): -$5.36M as of Jun 30, 2020
Free cash flow (TTM): -$6.18M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 110,430,630 as of Jul 28, 2020
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.